Silence Therapeutics Plc (SLNCF) Stock Price & Analysis
Silence Therapeutics Plc (SLNCF) rose 0.00% to USD 1.06 as of June 10, 2026 at 06:02 UTC, according to Nexqual real-time market data.
SLNCF last closed at USD 1.06; the session ranged USD 1.06–1.06 on volume of 130 shares. Market capitalization is $150.21M, with a 52-week range of USD 1.06–2.63 (PNK). Source: Nexqual, June 10, 2026 at 06:02 UTC.
Key Statistics (as of June 10, 2026 at 06:02 UTC)
| Price | USD 1.06 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.06 |
| Open | USD 1.06 |
| Day Range | USD 1.06 – 1.06 |
| 52-Week Range | USD 1.06 – 2.63 |
| Volume | 130 shares |
| Market Cap | $150.21M |
| Exchange | PNK |
Technical Analysis (SLNCF)
Nexqual's technical model rates SLNCF "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 12.29 (oversold) |
| vs SMA50 | Below (USD 1.88) |
| MACD | -0.27 (negative) |
Analyst Ratings (SLNCF)
Wall Street analysts rate SLNCF "None", per Nexqual as of June 10, 2026 at 06:02 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SLNCF)
| Revenue Estimate | $1.04M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.07 vs est -0.08 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financials & Fundamentals (SLNCF)
| Total Revenue | $839,000 |
|---|---|
| Revenue Growth (YoY) | +197.20% |
| Gross Margin | +79.50% |
| Operating Margin | -3565.40% |
| Profit Margin | +0.00% |
| ROE | -92.56% |
| Debt / Equity | 0.28 |
| Current Ratio | 9.83 |
| Total Cash | $70.08M |
| Total Debt | $136,000 |
| Free Cash Flow | $-44.56M |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financial Health Score (SLNCF)
Nexqual rates Silence Therapeutics Plc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:02 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $70M cash, no debt |
| Cash Flow | Weak — FCF negative: -$45M, burning cash |
| Efficiency | Critical — ROE -93%, ROA -29.8% |
Ownership (SLNCF)
| Insider Ownership | +8.76% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 141.70M |
| Float | 74.75M |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Leadership (SLNCF)
Silence Therapeutics Plc is led by Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71), Interim CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 06:02 UTC.
| Interim CEO & Chairman of the Board | Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71) |
|---|---|
| Executive VP, CFO, Secretary & Executive Director | Rhonda L. Hellums (age 54) |
| Chief Scientific Officer | Marie Wikstrom Lindholm |
From Silence Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
- The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
- It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTCHF | PureTech Health PLC | USD 1.8 | ▼ 3.33% |
| SLN | Silence Therapeutics Plc - Amer | USD 6.01 | ▼ 2.59% |
| PHGUF | Pharming Group NV | USD 1.18 | ▲ 0% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| SPHRY | Starpharma Holdings Ltd. | USD 5.1 | ▼ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:02 UTC. This page is informational and not investment advice.